# EDGAR Filing Document

**Accession Number:** 0001868726
**File Stem:** 0001868726-26-000006
**Filing Date:** 2026-3
**Character Count:** 37930
**Document Hash:** 7704e9bf931287600b43b00029a7b4ff
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001868726-26-000006.hdr.sgml**: 20260305

**ACCESSION NUMBER**: 0001868726-26-000006

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20260305

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260305

**DATE AS OF CHANGE**: 20260305

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** OLAPLEX HOLDINGS, INC.
- **CENTRAL INDEX KEY:** 0001868726
- **STANDARD INDUSTRIAL CLASSIFICATION:** PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40860
- **FILM NUMBER:** 26724134

**BUSINESS ADDRESS:**
- **STREET 1:** 432 PARK AVENUE SOUTH
- **STREET 2:** THIRD FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10016
- **BUSINESS PHONE:** 310-691-0776

**MAIL ADDRESS:**
- **STREET 1:** 432 PARK AVENUE SOUTH
- **STREET 2:** THIRD FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10016

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** OLAPEX HOLDINGS, INC.
- **DATE OF NAME CHANGE:** 20210622

?xml version='1.0' encoding='ASCII'? olpx-20260305

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM 8-K** 

**CURRENT REPORT** 

**Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934** 

**Date of Report (Date of earliest event reported)**: **March 5, 2026** 

**Olaplex Holdings, Inc.**

**(Exact name of registrant as specified in its charter)** 

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-40860** | **87-1242679** |
| **(State or other jurisdiction**<br>**of incorporation)** | **(Commission File Number)** | **(IRS Employer Identification No.)** |

---

432 Park Avenue South, Third Floor, New York, NY 10016

**(Address of principal executive offices) (Zip Code)** 

**Registrant's telephone number, including area code: (310) 691-0776**

**Not applicable** 

**(Former name or former address, if changed since last report.)** 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol** | **Name of each exchange on which registered** |
| **Common Stock, par value $0.001 per share** | **OLPX** | **Nasdaq Global Select Market** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.02 Results of Operations and Financial Condition.**

On March 5, 2026, Olaplex Holdings, Inc. (the "Company") issued a press release announcing its results of operations for the fourth quarter and fiscal year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished under Item 2.02 of this Current Report on Form 8-K, including the exhibit, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference into any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit** | **Description** |
| <u>[99.1](olpx-20251231xex991.htm)</u> | <u>[Press Release dated March 5, 2026.](olpx-20251231xex991.htm)</u> |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**Signature**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: March 5, 2026 | Olaplex Holdings, Inc. | Olaplex Holdings, Inc. |
|  | By: | /s/ Amanda Baldwin |
|  | Name: | Amanda Baldwin |
|  | Title: | Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**OLAPLEX Reports Fourth Quarter and Fiscal Year 2025 Results**

**NEW YORK, NY – March 5, 2026** – Olaplex Holdings, Inc. (NASDAQ: OLPX) ("OLAPLEX" or the "Company") today announced financial results for the fourth quarter and fiscal year ended December 31, 2025.

Amanda Baldwin, OLAPLEX's Chief Executive Officer, commented: "We ended 2025 on a high note with fourth quarter sales growth of 4.3%. In 2025, we delivered on our Bonds & Beyond transformation priorities, driving renewed brand momentum and building a consistent innovation pipeline while strengthening execution and sharpening strategic focus. As we enter 2026, we do so with a clear path forward and a more balanced, sustainable approach to investment and growth."

**For the fourth quarter of 2025 compared to the fourth quarter of 2024:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**•** Net sales increased 4.3% to $105.1 million;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ By channel:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ Specialty Retail decreased 14.5% to $24.7 million;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ Professional increased 18.9% to $36.8 million;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ Direct-To-Consumer increased 6.6% to $43.6 million;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ Net sales increased 0.8% in the United States and increased 7.6% internationally;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net loss was $13.1 million, as compared to $8.8 million for the fourth quarter of 2024;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Diluted net loss per share was $(0.02), as compared to $(0.01) for the fourth quarter of 2024.

**For the fiscal year 2025 compared to the fiscal year 2024:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**•** Net sales increased 0.1% to $423.0 million;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ By channel:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ Specialty Retail decreased 8.3% to $130.4 million;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ Professional increased 5.5% to $153.3 million;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ Direct-To-Consumer increased 3.1% to $139.3 million;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net loss was $9.3 million, as compared to net income of $19.5 million for 2024;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Diluted net (loss) income per share was $(0.01), as compared to $0.03 for 2024.

**Three Months Ended December 31, 2025 Results**

---

| | | | |
|:---|:---|:---|:---|
| **<u>(Amounts in thousands, except per share data)</u>** | | | |
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | |
|  | **2025** | **2024** | **% Change** |
| Net Sales | $105119  | $100741  | 4.3% |
| Gross Profit | $71457  | $66776  | 7.0% |
| Gross Profit Margin | 68.0% | 66.3% |  |
| Adjusted Gross Profit | $74162  | $69064  | 7.4% |
| Adjusted Gross Profit Margin | 70.6% | 68.6% |  |
| SG&A | $65107  | $52869  | 23.1% |
| Adjusted SG&A | $61415  | $50306  | 22.1% |
| Net Loss | $(13102) | $(8800) | 48.9% |
| Adjusted Net Income | $5560  | $7630  | (27.1)% |
| Adjusted EBITDA | $12861  | $17489  | (26.5)% |
| Adjusted EBITDA Margin | 12.2% | 17.4% |  |
| Diluted Net Loss Per Share | $(0.02) | $(0.01) | 100.0% |
| Adjusted Diluted Net Income Per Share | $0.01  | $0.01  | —% |

---

------

**Fiscal Year 2025 Results**

---

| | | | |
|:---|:---|:---|:---|
| **<u>(Amounts in thousands, except per share data)</u>** | | | |
| | **Year Ended December 31,** | **Year Ended December 31,** | |
|  | **2025** | **2024** | **% Change** |
| Net Sales | $422960  | $422670  | 0.1% |
| Gross Profit | $293646  | $292290  | 0.5% |
| Gross Profit Margin | 69.4% | 69.2% |  |
| Adjusted Gross Profit | $303631  | $301632  | 0.7% |
| Adjusted Gross Profit Margin | 71.8% | 71.4% |  |
| SG&A | $243113  | $181685  | 33.8% |
| Adjusted SG&A | $211375  | $170550  | 23.9% |
| Net (Loss) Income | $(9252) | $19522  | (147.4)% |
| Adjusted Net Income | $51383  | $75713  | (32.1)% |
| Adjusted EBITDA | $93869  | $129665  | (27.6)% |
| Adjusted EBITDA Margin | 22.2% | 30.7% |  |
| Diluted Net (Loss) Income Per Share | $(0.01) | $0.03  | (133.3)% |
| Adjusted Diluted Net Income Per Share | $0.08  | $0.11  | (27.3)% |

---

Adjusted gross profit, adjusted gross profit margin, adjusted SG&A, adjusted net income, adjusted EBITDA, adjusted EBITDA margin and adjusted diluted net income per share are measures that are not calculated or presented in accordance with generally accepted accounting principles in the United States of America ("GAAP"). For more information about how we use these non-GAAP financial measures in our business, the limitations of these measures, and a reconciliation of these measures to the most directly comparable GAAP measures, please see "Disclosure Regarding Non-GAAP Financial Measures" and the reconciliation tables that accompany this release.

**Balance Sheet**

As of December 31, 2025, the Company had $318.7 million of cash and cash equivalents, compared to $586.0 million as of December 31, 2024. Inventory at the end of the fourth quarter of 2025 was $60.2 million, compared to $75.2 million at December 31, 2024. Long-term debt, net of current portion and deferred debt issuance costs was $352.3 million as of December 31, 2025, compared to $643.7 million as of December 31, 2024.

**Fiscal Year 2026 Guidance**

The Company's fiscal year 2026 guidance below assumes no material impact from tariffs or the current geopolitical environment. The fiscal year 2026 net sales guidance below also reflects management's expectation that the net sales performance for the first quarter will trend below the expected net sales performance for the full fiscal year 2026, on a percentage basis, with consumer demand expected to be weighted towards the second half of the year as strategic initiatives take effect. Further, management expects that adjusted EBITDA margin in the first quarter will trend significantly below the expected adjusted EBITDA margin for the full fiscal year 2026, as marketing spend is expected to be front loaded in fiscal year 2026.

---

| | | |
|:---|:---|:---|
| **For Fiscal 2026:** | | |
| **<u>(Dollars in millions)</u>** | **<u>2026</u>** | **<u>2025 Actual</u>** |
| Net Sales | $414 - $435 | $423 |
| Adjusted Gross Profit Margin\* | 71% to 72% | 71.8% |
| Adjusted EBITDA Margin\* | 21% to 22% | 22.2% |

---

\*Adjusted gross profit margin and adjusted EBITDA margin are non-GAAP measures. See "Disclosure Regarding Non-GAAP Financial Measures" for additional information.

------

**Webcast and Conference Call Information**

The Company plans to host an investor conference call and webcast to review fourth quarter and fiscal 2025 financial results at 9:00am ET/6:00am PT on March 5, 2026. The webcast can be accessed at <u>https://ir.olaplex.com</u>. The conference call can be accessed by calling (201) 689-8521 or (877) 407-8813 for a toll-free number. A replay of the webcast will remain available on the website for 90 days.

**About OLAPLEX** 

**Cautionary Note Regarding Forward-Looking Statements**

This press release includes certain forward-looking statements and information relating to the Company that are based on the beliefs of management as well as assumptions made by, and information currently available to, the Company. These forward-looking statements include, but are not limited to, statements about: the Company's financial position, operating results, growth, sales and profitability, including revenue shifts across channels; the Company's financial guidance for fiscal year 2026, including net sales, adjusted gross profit margin and adjusted EBITDA margin; the Company's expectations regarding net sales and adjusted EBITDA margin for the first quarter 2026; the Company's financial position, profitability, sell-through, operating expenses and growth; demand for the Company's products; the Company's innovation strategy and pipeline; the Company's international strategy and operations; the Company's business transformation plans, strategies, investments, priorities and objectives, including the impact and timing thereof; the Company's packaging redesign initiative; the Company's capital allocation opportunities; the Company's sales, marketing, promotion and education initiatives and related investments, and the impact, focus and timing thereof; general economic and industry trends, including tariffs; sales channels; inventory levels; and other statements contained in this press release that are not historical or current facts. When used in this press release, words such as "may," "will," "could," "should," "intend," "potential," "continue," "anticipate," "believe," "estimate," "expect," "plan," "target," "predict," "project," "forecast," "seek" and similar expressions as they relate to the Company are intended to identify forward-looking statements.

The forward-looking statements in this press release reflect the Company's current expectations and projections about future events and financial trends that management believes may affect the Company's business, financial condition and results of operations. These statements are predictions based upon assumptions that may not prove to be accurate, and they are not guarantees of future performance. As such, you should not place significant reliance on the Company's forward-looking statements. Neither the Company nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements, including any such statements taken from third party industry and market reports.

Forward-looking statements involve known and unknown risks, inherent uncertainties and other factors that are difficult to predict which may cause the Company's actual results, performance, time frames or achievements to be materially different from any future results, performance, time frames or achievements expressed or implied by the forward-looking statements, including, without limitation: the Company's dependence on the success of its business transformation plan; competition in the beauty industry; the Company's ability to effectively maintain and promote a positive brand image, expand its brand awareness and maintain consumer confidence in the quality, safety and efficacy of its products; the Company's ability to anticipate and respond to market trends and changes in consumer preferences and execute on its growth strategies and expansion opportunities, including with respect to new product introductions; the Company's ability to develop, manufacture and effectively and profitably market and sell future products; the Company's ability to attract new customers and consumers and encourage consumer spending across its product portfolio; the Company's ability to successfully implement new or additional marketing efforts; the Company's relationships with and the capabilities and performance of its suppliers, manufacturers, distributors and retailers and the Company's ability to manage its supply chain, including sourcing, manufacturing and quality control; the Company's dependence on a limited number of customers for a large portion of its net sales; the Company's ability to limit the illegal distribution and sale by third parties of counterfeit versions of its products or the unauthorized diversion by third parties of its products; the Company's ability to accurately forecast customer and consumer demand for its products; impacts on the Company's business from political, regulatory, economic, trade and other risks associated with operating internationally; the Company's ability to attract and retain senior management and other qualified personnel; the Company's reliance on its and its third-party service providers' information

------

technology; the Company's ability to maintain the security of confidential information; the Company's ability to establish and maintain intellectual property protection for its products, as well as the Company's ability to operate its business without infringing, misappropriating or otherwise violating the intellectual property rights of others; the outcome of litigation and regulatory proceedings; the impact of changes in federal, state and international laws, regulations and administrative policy, tariffs and other trade policies; the Company's existing and any future indebtedness, including the Company's ability to comply with affirmative and negative covenants under its credit agreement; the Company's ability to service its existing indebtedness and obtain additional capital to finance operations and its growth opportunities; volatility of the Company's stock price; the Company's "controlled company" status and the influence of investment funds affiliated with Advent International, L.P. over the Company; the impact of general economic conditions, disruptions in business conditions, and the financial strength of the Company's consumers and customers on the Company's business; fluctuations in the Company's quarterly results of operations; changes in the Company's tax rates and the Company's exposure to tax liability; the Company's ability to integrate or realize the intended benefits of its acquisitions or strategic investments; and the other factors identified under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") and in the other documents that the Company files with the SEC from time to time.

Many of these factors are macroeconomic in nature and are, therefore, beyond the Company's control. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, the Company's actual results, performance or achievements may vary materially from those described in this press release as anticipated, believed, estimated, expected, intended, planned or projected. The forward-looking statements in this press release represent management's views as of the date hereof. Unless required by law, the Company neither intends nor assumes any obligation to update these forward-looking statements for any reason after the date hereof to conform these statements to actual results or to changes in the Company's expectations or otherwise.

**Disclosure Regarding Non-GAAP Financial Measures** 

In addition to the financial measures presented in this release in accordance with GAAP, the Company has included certain non-GAAP financial measures, including adjusted EBITDA, adjusted EBITDA margin, adjusted gross profit, adjusted gross profit margin, adjusted SG&A, adjusted net income and adjusted basic and diluted net income per share. Management believes these non-GAAP financial measures, when taken together with the Company's financial results presented in accordance with GAAP, provide meaningful supplemental information regarding the Company's operating performance and facilitate internal comparisons of its historical operating performance on a more consistent basis by excluding certain items that may not be indicative of its business, results of operations or outlook. In particular, management believes that the use of these non-GAAP measures may be helpful to investors as they are measures used by management in assessing the health of the Company's business, determining incentive compensation and evaluating its operating performance, as well as for internal planning and forecasting purposes.

The Company calculates adjusted EBITDA as net income (loss), adjusted to exclude: (1) interest expense, net; (2) income tax provision (benefit); (3) depreciation and amortization; (4) share-based compensation expense; (5) certain litigation-related expenses; (6) acquisition-related costs; (7) executive reorganization costs and (8) Tax Receivable Agreement liability adjustments. The Company calculates adjusted EBITDA margin by dividing adjusted EBITDA by net sales. The Company calculates adjusted gross profit as gross profit, adjusted to exclude amortization of patented formulations. The Company calculates adjusted gross profit margin by dividing adjusted gross profit by net sales. The Company calculates adjusted SG&A as SG&A, adjusted to exclude: (1) share-based compensation expense; (2) certain litigation-related expenses; (3) acquisition-related costs and (4) executive reorganization costs. The Company calculates adjusted net income as net income (loss), adjusted to exclude: (1) amortization of intangible assets (excluding software); (2) share-based compensation expense; (3) certain litigation-related expenses; (4) acquisition-related costs; (5) executive reorganization costs; (6) deferred debt issuance costs write-offs; (7) Tax Receivable Agreement liability adjustments; and (8) tax effect of non-GAAP adjustments. The Company calculates adjusted basic and diluted net income per share as adjusted net income divided by weighted average basic and diluted shares outstanding, respectively. Please refer to "Reconciliation of Non-GAAP Financial Measures to GAAP Equivalents" located in the financial supplement in this release for further information regarding these adjustments for the periods presented.

Please refer to "Reconciliation of Non-GAAP Financial Measures to GAAP Equivalents" located in the financial supplement in this release for a reconciliation of these non-GAAP metrics to their most directly comparable financial measure stated in accordance with GAAP.

This release includes forward-looking guidance for adjusted EBITDA margin and adjusted gross profit margin. The Company is not able to provide, without unreasonable effort, a reconciliation of the guidance for adjusted EBITDA margin and adjusted gross profit margin to the most directly comparable GAAP measure because the Company does not currently have sufficient data to accurately estimate the variables and individual adjustments included in the most directly comparable GAAP measure that would

------

be necessary for such reconciliations, including (a) costs related to potential debt or equity transactions and (b) other non-recurring expenses that cannot reasonably be estimated in advance. These adjustments are inherently variable and uncertain and depend on various factors that are beyond the Company's control and as a result it is also unable to predict their probable significance. Therefore, because management cannot estimate on a forward-looking basis without unreasonable effort the impact these variables and individual adjustments will have on its reported results in accordance with GAAP, it is unable to provide a reconciliation of the non-GAAP financial measures included in its fiscal year 2026 guidance.

------

**CONDENSED CONSOLIDATED BALANCE SHEETS** 

*(amounts in thousands, except per share and share data)* 

*(Unaudited)*

---

| | | |
|:---|:---|:---|
|  | **December 31,<br>2025** | **December 31,<br>2024** |
| **Assets** |  | |
| Current Assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $318731  | $585967  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net of allowances of $18,123 and $15,859 | 29013  | 14934  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventory | 60215  | 75165  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 62387  | 13647  |
| Total current assets | 470346  | 689713  |
| Property and equipment, net | 1422  | 1442  |
| Intangible assets, net | 847821  | 899549  |
| Goodwill | 168300  | 168300  |
| Deferred tax assets | 46  | —  |
| Other assets | 9552  | 8719  |
| Total assets | $1497487  | $1767723  |
| **Liabilities and stockholders' equity** |  |  |
| Current Liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | $8117  | $10423  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses and other current liabilities | 85304  | 35639  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Current portion of long-term debt | —  | 6750  |
| &nbsp;&nbsp;&nbsp;&nbsp;Current portion of Related Party payable pursuant to Tax Receivable Agreement | 9206  | 11842  |
| Total current liabilities | 102627  | 64654  |
| Long-term debt | 352290  | 643712  |
| Deferred tax liabilities | 5283  | 5164  |
| Related Party payable pursuant to Tax Receivable Agreement  | 155858  | 177469  |
| Other liabilities | 2039  | 2322  |
| Total liabilities | 618097  | 893321  |
| Commitments and Contingencies |  |  |
| Stockholders' equity:  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock, $0.001 par value per share; 2,000,000,000 shares authorized, 669,076,651 and 664,224,893 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 669  | 664  |
| &nbsp;&nbsp;&nbsp;&nbsp;Preferred stock, $0.001 par value per share; 25,000,000 shares authorized and no shares issued and outstanding as of December 31, 2025 and 2024, respectively | —  | —  |
| &nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in capital | 342345  | 328538  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive loss | (337) | (765) |
| &nbsp;&nbsp;&nbsp;&nbsp;Retained earnings | 536713  | 545965  |
| Total stockholders' equity | 879390  | 874402  |
| Total liabilities and stockholders' equity | $1497487  | $1767723  |

---

------

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME** 

*(amounts in thousands, except per share and share data)* 

*(Unaudited)*

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended**<br>**December 31,** | **Three Months Ended**<br>**December 31,** | **Year Ended<br>December 31,** | **Year Ended<br>December 31,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Net sales | $105119  | $100741  | $422960  | $422670  |
| Cost of sales: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cost of product (excluding amortization) | 30957  | 31677  | 119329  | 121038  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of patented formulations | 2705  | 2288  | 9985  | 9342  |
| Total cost of sales | 33662  | 33965  | 129314  | 130380  |
| Gross profit | 71457  | 66776  | 293646  | 292290  |
| Operating expenses: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Selling, general, and administrative | 65107  | 52869  | 243113  | 181685  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of other intangible assets | 10854  | 10862  | 43582  | 43669  |
| Total operating expenses | 75961  | 63731  | 286695  | 225354  |
| Operating (loss) income | (4504) | 3045  | 6951  | 66936  |
| Interest expense | 7551  | 14877  | 41342  | 59585  |
| Interest income | (2659) | (6312) | (14828) | (25379) |
| Other (income) expense, net: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Tax Receivable Agreement liability adjustment | (2666) | 3915  | (12118) | 3915  |
| &nbsp;&nbsp;&nbsp;&nbsp;Other (income) expense, net | (37) | 1362  | (1268) | 1903  |
| Total other (income) expense, net | (2703) | 5277  | (13386) | 5818  |
| (Loss) income before income taxes | (6693) | (10797) | (6177) | 26912  |
| Income tax provision (benefit) | 6409  | (1997) | 3075  | 7390  |
| Net (loss) income | $(13102) | $(8800) | $(9252) | $19522  |
| Net (loss) income per share: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic | $(0.02) | $(0.01) | $(0.01) | $0.03  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted | $(0.02) | $(0.01) | $(0.01) | $0.03  |
| Weighted average common shares outstanding: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic | 668087032  | 663154824  | 666459101  | 661980612  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted | 668087032  | 663154824  | 666459101  | 665397655  |
| Other comprehensive income (loss): |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Unrealized gain (loss) on derivatives, net of income tax effect | $151  | $220  | $428  | $(2130) |
| Total other comprehensive income (loss) | 151  | 220  | 428  | (2130) |
| Comprehensive (loss) income | $(12951) | $(8580) | $(8824) | $17392  |

---

------

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS** 

*(amounts in thousands)*

*(Unaudited)*

---

| | | |
|:---|:---|:---|
| | **Year Ended**<br>**December 31,** | **Year Ended**<br>**December 31,** |
|  | **2025** | **2024** |
| Cash flows from operating activities |  |  |
| Net (loss) income | $(9252) | $19522  |
| Adjustments to reconcile net (loss) income to net cash provided by operating activities: | 67912  | 123546  |
| Net cash provided by operating activities | 58660  | 143068  |
| Net cash used in investing activities | (12606) | (4891) |
| Net cash used in financing activities | (313290) | (18610) |
| Net (decrease) increase in cash and cash equivalents | (267236) | 119567  |
| Cash and cash equivalents - beginning of year | 585967  | 466400  |
| Cash and cash equivalents - end of year | $318731  | $585967  |

---

**Reconciliation of Non-GAAP Financial Measures to GAAP Equivalents**

*(amounts in thousands, except per share and share data)*

*(Unaudited)*

The following tables present a reconciliation of net (loss) income, gross profit and SG&A, as the most directly comparable financial measure stated in accordance with U.S. GAAP, to adjusted EBITDA, adjusted EBITDA margin, adjusted gross profit, adjusted gross profit margin, adjusted SG&A, adjusted net income and adjusted net income per share for each of the periods presented.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended**<br>**December 31,** | **Three Months Ended**<br>**December 31,** | **Year Ended**<br>**December 31,** | **Year Ended**<br>**December 31,** |
| | **2025** | **2024** | **2025** | **2024** |
| ***Reconciliation of Net (Loss) Income to Adjusted EBITDA*** |  |  |  |  |
| Net (loss) income | $(13102) | $(8800) | $(9252) | $19522  |
| Depreciation and amortization of intangible assets | 13636  | 13243  | 53912  | 53497  |
| Interest expense, net | 4892  | 8565  | 26514  | 34206  |
| Income tax provision (benefit) | 6409  | (1997) | 3075  | 7390  |
| Share-based compensation expense | 3593  | 2563  | 13285  | 11123  |
| Certain litigation-related expenses<sup>(1)</sup> | 76  | —  | 9148  | —  |
| Acquisition-related costs<sup>(2)</sup> | 23  | —  | 9305  | —  |
| Executive reorganization cost<sup>(3)</sup> | —  | —  | —  | 12  |
| Tax Receivable Agreement liability adjustment | (2666) | 3915  | (12118) | 3915  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjusted EBITDA | $12861  | $17489  | $93869  | $129665  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjusted EBITDA margin | 12.2% | 17.4% | 22.2% | 30.7% |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended**<br>**December 31,** | **Three Months Ended**<br>**December 31,** | **Year Ended**<br>**December 31,** | **Year Ended**<br>**December 31,** |
| | **2025** | **2024** | **2025** | **2024** |
| ***Reconciliation of Gross Profit to Adjusted Gross Profit*** |  |  |  |  |
| Gross profit | $71457  | $66776  | $293646  | $292290  |
| Amortization of patented formulations | 2705  | 2288  | 9985  | 9342  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjusted gross profit | $74162  | $69064  | $303631  | $301632  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjusted gross profit margin | 70.6% | 68.6% | 71.8% | 71.4% |

---

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended**<br>**December 31,** | **Three Months Ended**<br>**December 31,** | **Year Ended**<br>**December 31,** | **Year Ended**<br>**December 31,** |
| | **2025** | **2024** | **2025** | **2024** |
| ***Reconciliation of SG&A to Adjusted SG&A*** |  |  |  |  |
| SG&A | $65107  | $52869  | $243113  | $181685  |
| Share-based compensation expense | (3593) | (2563) | (13285) | (11123) |
| Certain litigation-related expenses<sup>(1)</sup> | (76) | —  | (9148) | —  |
| Acquisition-related costs<sup>(2)</sup> | (23) | —  | (9305) | —  |
| Executive reorganization cost<sup>(3)</sup> | —  | —  | —  | (12) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjusted SG&A | $61415  | $50306  | $211375  | $170550  |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended**<br>**December 31,** | **Three Months Ended**<br>**December 31,** | **Year Ended**<br>**December 31,** | **Year Ended**<br>**December 31,** |
| | **2025** | **2024** | **2025** | **2024** |
| ***Reconciliation of Net (Loss) Income to Adjusted Net Income*** |  |  |  |  |
| Net (loss) income | $(13102) | $(8800) | $(9252) | $19522  |
| Amortization of intangible assets (excluding software) | 12888  | 12471  | 50715  | 50073  |
| Share-based compensation expense | 3593  | 2563  | 13285  | 11123  |
| Deferred debt issuance cost write-off<sup>(4)</sup> | —  | —  | 2573  | —  |
| Certain litigation-related expenses<sup>(1)</sup> | 76  | —  | 9148  | —  |
| Acquisition-related costs<sup>(2)</sup> | 23  | —  | 9305  | —  |
| Executive reorganization cost<sup>(3)</sup> | —  | —  | —  | 12  |
| Tax Receivable Agreement liability adjustment | (2666) | 3915  | (12118) | 3915  |
| Tax effect of adjustments  | 4748  | (2519) | (12273) | (8932) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjusted net income | $5560  | $7630  | $51383  | $75713  |
| Adjusted net income per share: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic | $0.01  | $0.01  | $0.08  | $0.11  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted | $0.01  | $0.01  | $0.08  | $0.11  |
| Weighted average diluted shares outstanding<sup>(5)</sup> | 669084977  | 667406963  | 667937971  | 665397655  |

---

(1)Represents litigation costs related to the *Lilien* securities class action. The Company considers litigation costs related to the *Lilien* securities class action, as described in Note 14 to the Company's Annual Report on Form 10-K for the year ended December 31, 2025, to be non-recurring and non-ordinary. While the Company did not adjust for these costs during the year ended December 31, 2024 because the amounts incurred in 2024 were not material, commencing with the three months ended March 31, 2025, the Company has included an adjustment for these costs as a result of the court's denial of the Company's motion to dismiss in February 2025. The Company believes adjusting for such costs provides investors with meaningful information regarding the Company's core operating performance.

(2)Represents non-recurring and non-ordinary costs related to the acquisition of all of the outstanding capital stock of Purvala Bioscience, Inc. ("Purvala") by Olaplex, Inc. on August 20, 2025.

(3)Represented benefit payments associated with the departure of the Company's Chief Executive Officer that occurred in fiscal year 2023 and Chief Operating Officer that occurred in fiscal year 2022.

(4)Represents the write-off of deferred debt issuance costs associated with the Company's $300.0 million voluntary repayment of outstanding principal on its term loan facility under the Company's credit agreement on May 1, 2025.

(5)Weighted average diluted shares outstanding for the three months and year ended December 31, 2025 and for the three months ended December 31, 2024 differ from the GAAP presentation on the Company's Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income due to the Company being in a loss position on an unadjusted basis.

------

**Contacts:**

**Investors:**

**Michael Oriolo**

**Vice President, Investor Relations**

**michael.oriolo@olaplex.com**

**Financial Media:**

**Lisa Bobroff**

**Vice President, Global Communications & Consumer Engagement**

**lisa.bobroff@olaplex.com**

<br>